LEVETIRACETAM - levetiracetam solution

Country: United States

Language: English

Source: NLM (National Library of Medicine)

Buy It Now

Active ingredient:

Levetiracetam (UNII: 44YRR34555) (Levetiracetam - UNII:44YRR34555)

Available from:

LLC Federal Solutions

INN (International Name):

Levetiracetam

Composition:

Levetiracetam 100 mg in 1 mL

Administration route:

ORAL

Prescription type:

PRESCRIPTION DRUG

Therapeutic indications:

INDICATION AND USAGE Levetiracetam is indicated as adjunctive therapy in the treatment of partial onset seizures in adults and children 4 years of age and older with epilepsy. Levetiracetam is indicated as adjunctive therapy in the treatment of myoclonic seizures in adults and adolescents 12 years of age and older with juvenile myoclonic epilepsy. Levetiracetam is indicated as adjunctive therapy in the treatment of primary generalized tonic-clonic seizures in adults and children 6 years of age and older with idiopathic generalized epilepsy. CONTRAINDICATIONS This product should not be administered to patients who have previously exhibited hypersensitivity to levetiracetam or any of the inactive ingredients in Levetiracetam Oral Solution. DRUG ABUSE AND DEPENDENCE The abuse and dependence potential of Levetiracetam has not been evaluated in human studies.

Product summary:

HOW SUPPLIED Levetiracetam Oral Solution, 100 mg/mL, is a clear, colorless, grape-flavored liquid, and supplied in a 5 mL unit dose cup. One-hundred (100) cups per box. Storage Store at 25°C (77°F); excursions permitted to 15° to 30°C (59° to 86°F) [see USP Controlled Room Temperature]. Pharmacist: Dispense in a tight, light resistant container with a child-resistant closure. Repackaged by: Safecor Health, LLC Woburn, MA 01801 Distributed by: LLC Federal Solutions Miami, FL 33132 Rev 110-00 09/2013

Authorization status:

Abbreviated New Drug Application

Patient Information leaflet

                                LEVETIRACETAM - LEVETIRACETAM SOLUTION
LLC Federal Solutions
----------
MEDICATION GUIDE
Levetiracetam 100 mg/mL Oral Solution
Read this Medication Guide before you start taking Levetiracetam Oral
Solution and each time you get a
refill. There may be new information. This information does not take
the place of talking to your
healthcare provider about your medical condition or treatment.
What is the most important information I should know about
Levetiracetam?
Like other antiepileptic drugs, Levetiracetam may cause suicidal
thoughts or actions in a very small
number of people, about 1 in 500 people taking it.
Call a healthcare provider right away if you have any of these
symptoms, especially if they are new,
worse, or worry you:
•
thoughts about suicide or dying
•
attempts to commit suicide
•
new or worse depression
•
new or worse anxiety
•
feeling agitated or restless
•
panic attacks
•
trouble sleeping (insomnia)
•
new or worse irritability
•
acting aggressive, being angry, or violent
•
acting on dangerous impulses
•
an extreme increase in activity and talking (mania)
•
other unusual changes in behavior or mood
Do not stop Levetiracetam without first talking to a healthcare
provider.
•
Stopping Levetiracetam suddenly can cause serious problems. Stopping a
seizure medicine
suddenly can cause seizures that will not stop (status epilepticus).
•
Suicidal thoughts or actions can be caused by things other than
medicines. If you have suicidal
thoughts or actions, your healthcare provider may check for other
causes.
How can I watch for early symptoms of suicidal thoughts and actions?
•
Pay attention to any changes, especially sudden changes, in mood,
behaviors, thoughts, or
feelings.
•
Keep all follow-up visits with your healthcare provider as scheduled.
•
Call your healthcare provider between visits as needed, especially if
you are worried about
symptoms.
What is Levetiracetam?
Levetiracetam is a medicine taken by mouth that is used with other
medicines to treat:
•
partial onset seiz
                                
                                Read the complete document
                                
                            

Summary of Product characteristics

                                LEVETIRACETAM - LEVETIRACETAM SOLUTION
LLC FEDERAL SOLUTIONS
----------
DESCRIPTION
Levetiracetam is an antiepileptic drug available as a clear,
colorless, grape-flavored liquid (100
mg/mL) for oral administration.
The chemical name of levetiracetam, a single enantiomer, is
(-)-(S)-α-ethyl-2-oxo-1-pyrrolidine
acetamide, its molecular formula is C H N O and its molecular weight
is 170.21. Levetiracetam is
chemically unrelated to existing antiepileptic drugs (AEDs). It has
the following structural formula:
Levetiracetam is a white to off-white crystalline powder with a faint
odor and a bitter taste. It is very
soluble in water (104.0 g/100 mL). It is freely soluble in chloroform
(65.3 g/100 mL) and in methanol
(53.6 g/100 mL), soluble in ethanol (16.5 g/100 mL), sparingly soluble
in acetonitrile (5.7 g/100 mL)
and practically insoluble in n-hexane. (Solubility limits are
expressed as g/100 mL solvent.)
Levetiracetam oral solution contains 100 mg of levetiracetam per mL.
Inactive ingredients: acesulfame
potassium, citric acid, flavor, glycerin, methylparaben,
propylparaben, purified water, sodium citrate,
and sorbitol solution.
CLINICAL PHARMACOLOGY
MECHANISM OF ACTION
The precise mechanism(s) by which levetiracetam exerts its
antiepileptic effect is unknown. The
antiepileptic activity of levetiracetam was assessed in a number of
animal models of epileptic seizures.
Levetiracetam did not inhibit single seizures induced by maximal
stimulation with electrical current or
different chemoconvulsants and showed only minimal activity in
submaximal stimulation and in threshold
tests. Protection was observed, however, against secondarily
generalized activity from focal seizures
induced by pilocarpine and kainic acid, two chemoconvulsants that
induce seizures that mimic some
features of human complex partial seizures with secondary
generalization. Levetiracetam also displayed
inhibitory properties in the kindling model in rats, another model of
human complex partial seizures,
both during kindling development and in the fully
                                
                                Read the complete document
                                
                            

Search alerts related to this product